Exosome therapy is at the forefront of cell-free regenerative science, offering targeted tissue repair through biological signalling vesicles. In Australia, the TGA's classification of exosome products under its biological therapeutics framework means domestic access is virtually non-existent. Our clinic in Chiang Mai provides Australian patients with regulated access to exosome therapy, with structured follow-up coordination with your GP and pathology monitoring at any Australian laboratory.
Exosome therapy uses cell-free extracellular vesicles to deliver regenerative signalling molecules directly to damaged tissue. As a cell-free biological, exosomes carry growth factors, RNA, and proteins that promote tissue repair without the complexity of live cell transplantation. Treatment involves targeted delivery of purified exosomes to affected areas, often combined with other regenerative modalities for enhanced outcomes. For a comprehensive understanding of the science, evidence, and treatment process, visit our full Exosome Therapy page.
The cell-free nature of exosome therapy appeals to Australian patients who want regenerative benefits with minimal downtime and lower immunological risk compared to cell-based treatments. Treatment programmes are shorter than stem cell protocols, typically three to five days, making it practical for patients travelling from overseas. English-speaking coordination, significant cost savings compared to any limited domestic options, and structured physician follow-up make the process straightforward.
Exosomes are nanoscale vesicles that carry biological signals between cells, promoting tissue repair and modulating inflammation without using whole cells.
Exosome therapy is cell-free, delivering only the signalling molecules rather than whole cells. This can offer advantages in terms of simplicity and minimal downtime.
Typically three to five days in Chiang Mai, including assessment and treatment sessions.
Yes. It is frequently combined with stem cell and anti-ageing protocols for synergistic benefits.
Minimal to none. Most patients resume normal activities immediately.
Exosome therapy has very limited availability in Australia. The TGA classifies exosome products as biological therapeutics requiring ARTG listing, and most are not listed. Thailand offers regulated access under medical supervision.
The TGA classifies exosome-based products under its biological medicines framework, requiring formal evaluation and ARTG listing before commercial use. This process is lengthy and most exosome products have not pursued or achieved listing, severely restricting domestic availability.
Yes. We provide comprehensive treatment summaries and follow-up blood work can be completed at any Australian pathology service. Results are reviewed by our clinical team and shared with your GP.
Exosome therapy is used for a range of applications including systemic inflammation reduction, tissue repair support, anti-ageing protocols, and musculoskeletal conditions. Your clinician will assess your suitability based on your medical history and goals.